<DOC>
	<DOC>NCT00545051</DOC>
	<brief_summary>This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly, with vitamin D and calcium supplementation. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>postmenopausal women, 5085 years of age; any inflammatory rheumatoid disease including polymyalgia rheumatica; receiving treatment with 515 mg/day of prednisolone. previous treatment with an iv bisphosphonate at any time; previous treatment with an oral bisphosphonate within the last 6 months, &gt;1 month of treatment within last year, or &gt;3 months of treatment within last 2 years; treatment with parathyroid hormone in last 2 years; inability to stand or sit in an upright position for at least 60 minutes; inability to swallow a tablet whole; history of major gastrointestinal disease.</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>